Clinical Trial Update: SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the SHP2 inhibitor BBP-398 in combination with sotorasib in patients with advanced KRAS-G12C-mutant solid tumors has been terminated;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BBP-398
• sotorasib (sotorasib)

Snippet

Sponsor: Navire Pharma Inc., a BridgeBio company | Conditions: Solid Tumor, Adult, Metastatic Solid Tumor | Phase 1 | Status: TERMINATED